Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 5, 2013

Primary Completion Date

November 7, 2016

Study Completion Date

April 25, 2017

Conditions
Facial Angiofibroma
Interventions
DRUG

Rapamycin

"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."

DRUG

Calcitriol

"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."

DRUG

Rapamycin-calcitriol combination

"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT03140449 - Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis | Biotech Hunter | Biotech Hunter